The Global Melanoma Therapeutics Market was valued at USD 3936.70 Million in 2023 and is projected to reach USD 9131.74 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 9.80% during the forecast period (2023–2032). This growth is being driven by the rising incidence of melanoma due to increased UV exposure and aging populations, advancements in immunotherapy and targeted therapies, and expanding access to precision medicine across hospitals and clinics worldwide.
As the oncology landscape evolves toward more precise, effective, and patient-centric treatments, attention turns to the pharmaceutical powerhouses leading the charge against this deadly form of skin cancer. In this blog, we profile the Top 10 Companies in the Melanoma Therapeutics Market—a blend of global biotech innovators and pharma giants pioneering immunotherapies, targeted inhibitors, and combination regimens that are transforming outcomes for melanoma patients.
🔟 1. AB Science
Headquarters: Paris, France
Key Offering: Masitinib (targeted therapy for advanced melanoma)
AB Science is a French biopharmaceutical company focused on innovative treatments for oncology and inflammatory diseases. In the melanoma space, it is advancing masitinib, a tyrosine kinase inhibitor that targets c-Kit mutations often found in mucosal and acral melanomas, offering potential for patients with limited options in later-stage disease.
Research Initiatives:
-
Ongoing Phase 3 trials evaluating masitinib in combination with standard therapies
-
Focus on rare melanoma subtypes, including orphan drug designations
-
Collaborations with academic centers for biomarker-driven patient selection
Download FREE Sample Report: Melanoma Therapeutics Market – View in Detailed Research Report
9️⃣ 2. Daiichi Sankyo Company Limited
Headquarters: Tokyo, Japan
Key Offering: Antibody-drug conjugates and targeted therapies for solid tumors including melanoma
Daiichi Sankyo, a leading Japanese pharmaceutical firm, is expanding its oncology portfolio with precision therapies. While best known for Enhertu in breast cancer, the company is investigating similar ADCs for melanoma, leveraging its expertise in linker technology to deliver cytotoxic payloads directly to cancer cells, potentially improving efficacy while minimizing systemic toxicity.
Research Initiatives:
-
Early-stage clinical trials for DS-8201 derivatives in BRAF-mutated melanomas
-
Global partnerships for combination studies with checkpoint inhibitors
8️⃣ 3. Incyte Corporation
Headquarters: Wilmington, Delaware, USA
Key Offering: Jakafi (ruxolitinib) and investigational IDO inhibitors for immunotherapy enhancement
Incyte Corporation specializes in small-molecule therapeutics for cancer and inflammation. In melanoma, its pipeline includes agents that modulate the tumor microenvironment, such as IDO1 inhibitors like epacadostat, which aim to boost the effectiveness of PD-1 therapies by reducing immune suppression in the tumor site.
Research Initiatives:
-
Phase 3 trials combining epacadostat with pembrolizumab
-
Exploration of JAK inhibitors to address resistance mechanisms in advanced melanoma
-
Focus on expanding indications to include uveal melanoma
7️⃣ 4. Pfizer Inc.
Headquarters: New York, New York, USA
Key Offering: Braftovi (encorafenib) and Mektovi (binimetinib) for BRAF V600E-mutant melanoma
Pfizer, a global biopharma leader, acquired Array BioPharma to bolster its oncology lineup. The Braftovi-Mektovi combination has become a cornerstone for treating unresectable or metastatic BRAF-mutant melanoma, demonstrating superior progression-free survival in clinical studies compared to older BRAF inhibitors alone.
Research Initiatives:
-
Approval for adjuvant therapy in high-risk stage II/III melanoma
-
Ongoing trials for combinations with immunotherapies
-
Investment in next-generation MEK inhibitors to overcome resistance
Download FREE Sample Report: Melanoma Therapeutics Market – View in Detailed Research Report
6️⃣ 5. Amgen Inc.
Headquarters: Thousand Oaks, California, USA
Key Offering: Imlygic (talimogene laherparepvec), an oncolytic viral therapy for advanced melanoma
Amgen, renowned for biologics in oncology and inflammation, introduced Imlygic as the first FDA-approved oncolytic immunotherapy for melanoma. This herpes virus-based treatment is injected directly into tumors, stimulating a systemic immune response that can target both injected and distant lesions, particularly beneficial for patients with inoperable disease.
Research Initiatives:
-
Combination studies with checkpoint inhibitors showing enhanced response rates
-
Exploration of oncolytic viruses for neoadjuvant settings
5️⃣ 6. AstraZeneca PLC
Headquarters: Cambridge, United Kingdom
Key Offering: Imfinzi (durvalumab) and Imlygic (talimogene laherparepvec) for immunotherapy in melanoma
AstraZeneca is a powerhouse in respiratory, oncology, and cardiovascular therapeutics. Through its acquisition of MediVector and partnerships, it has positioned Imlygic and PD-L1 inhibitors like Imfinzi to address unmet needs in melanoma, focusing on combinations that harness the body’s immune system more effectively against metastatic disease.
Research Initiatives:
-
Global trials for triple combinations including CTLA-4 and PD-L1 inhibitors
-
Biomarker research to predict responders to oncolytic therapies
4️⃣ 7. Novartis AG
Headquarters: Basel, Switzerland
Key Offering: Tafinlar (dabrafenib) and Mekinist (trametinib) for BRAF-mutant melanoma
Novartis, a Swiss multinational, leads in innovative medicines across multiple therapeutic areas. Its BRAF/MEK inhibitor duo, Tafinlar and Mekinist, is approved for both metastatic and adjuvant use in melanoma, significantly improving overall survival rates by blocking key signaling pathways in cancer cell growth.
Research Initiatives:
-
Expansion to pediatric and rare melanoma indications
-
Trials combining with IO agents for synergistic effects
-
Investment in CAR-T cell therapies for solid tumors like melanoma
Download FREE Sample Report: Melanoma Therapeutics Market – View in Detailed Research Report
3️⃣ 8. Roche Holding AG
Headquarters: Basel, Switzerland
Key Offering: Tecentriq (atezolizumab) and Cotellic (cobimetinib) for immunotherapy and targeted therapy
Roche, via its Genentech subsidiary, is a pioneer in biotechnology. Tecentriq, a PD-L1 inhibitor, has transformed melanoma treatment through combinations like Tecentriq with Cotellic and Zelboraf for BRAF V600-mutant cases, offering robust data on durable responses and manageable safety profiles in advanced settings.
Research Initiatives:
-
IMspire150 trial results supporting PD-L1 + BRAF/MEK regimens
-
Development of bispecific antibodies for dual immune targeting
2️⃣ 9. Bristol-Myers Squibb Company
Headquarters: New York, New York, USA
Key Offering: Opdivo (nivolumab) and Yervoy (ipilimumab) for checkpoint inhibitor immunotherapy
Bristol-Myers Squibb is at the forefront of immuno-oncology. Opdivo, a PD-1 inhibitor, alone or in combination with Yervoy (CTLA-4 inhibitor), has set new standards in melanoma therapy, with landmark trials like CheckMate-067 demonstrating unprecedented long-term survival benefits for patients with unresectable or metastatic disease.
Research Initiatives:
-
Approval for adjuvant therapy in high-risk resected melanoma
-
Over 50 ongoing trials exploring Opdivo-based combinations
-
Focus on overcoming primary and acquired resistance through novel combos
1️⃣ 10. Merck & Co. Inc.
Headquarters: Kenilworth, New Jersey, USA
Key Offering: Keytruda (pembrolizumab) for PD-1 inhibition across melanoma stages
Merck & Co., known as MSD outside the US, dominates with Keytruda, the first PD-1 inhibitor approved for melanoma. Its broad label spans adjuvant treatment post-resection to advanced metastatic cases, backed by extensive data showing improved recurrence-free survival and overall efficacy in first-line settings.
Research Initiatives:
-
KEYNOTE trials establishing monotherapy and combo standards
-
Expansion into neoadjuvant and uveal melanoma applications
-
Pipeline integrations with LAG-3 and other novel immunotherapies
Read Full Report: Melanoma Therapeutics Market – View in Detailed Research Report
🌍 Outlook: The Future of Melanoma Therapeutics Is More Targeted and Personalized
The melanoma therapeutics market is experiencing profound transformation. While traditional chemotherapy recedes, the sector pours resources into immunotherapies, targeted agents, and emerging modalities like oncolytic viruses and CAR-T cells, supported by genomic profiling to tailor treatments to individual mutations.
📈 Key Trends Shaping the Market:
-
Surge in combination therapies blending checkpoint inhibitors with targeted drugs
-
Regulatory approvals accelerating for adjuvant and neoadjuvant uses
-
Integration of AI and biomarkers for precision patient stratification
-
Pharma collaborations to tackle rare subtypes like uveal and mucosal melanoma
Market Trends Affecting Melanoma Therapeutics
-
Advancements in immunotherapy combinations — Dual blockade of PD-1 and CTLA-4 remains a benchmark, but newer pairings with LAG-3 or TIGIT inhibitors promise deeper responses. Companies like Bristol-Myers Squibb and Merck are leading with Phase 3 data showing improved durability.
-
Rise of targeted therapies for non-BRAF mutations — Beyond BRAF/MEK inhibitors from Novartis and Pfizer, research into NRAS and KIT-targeted agents addresses a larger patient pool. Roche’s efforts in this area highlight the shift toward broader genomic coverage.
-
Expansion into early-stage disease — Adjuvant immunotherapies are preventing recurrences effectively, with Keytruda and Opdivo approvals reshaping standards of care. This trend reduces the burden of metastatic progression and improves long-term survival rates.
-
Focus on overcoming resistance — Acquired resistance to both IO and targeted therapies drives innovation in sequential and adaptive regimens. AstraZeneca and Amgen’s work on oncolytic viruses offers a novel angle to resensitize tumors to immune attack.
-
Global access and equity initiatives — With melanoma incidence rising in emerging markets, companies like Novartis are partnering for affordable generics and trials in Asia-Pacific, ensuring therapies reach diverse populations amid varying UV exposure risks.
Read Full Report: Melanoma Therapeutics Market – View in Detailed Research Report
The companies listed above are not only treating melanoma—they’re spearheading the personalized oncology revolution, turning a once-fatal diagnosis into a manageable condition for many patients.